Baxter moves from drips to stem cell research
Baxter International Inc. (BAX.N: Quote, Profile, Research), a pioneer in intravenous drips, is quietly entering the complex, but promising field of stem cell research.
Though Baxter Chief Executive Robert Parkinson characterizes the trial as a "wild card," the ability to coax stem cells to grow into healthy heart tissue represents a $1 billion market opportunity that could transform the 75-year-old hospital products company.
<a href="http://www.reuters.com/article/health-SP/idUSN1344003720070418">Baxter moves from drips to stem cell research</a> (reuters.com)
Though Baxter Chief Executive Robert Parkinson characterizes the trial as a "wild card," the ability to coax stem cells to grow into healthy heart tissue represents a $1 billion market opportunity that could transform the 75-year-old hospital products company.
<a href="http://www.reuters.com/article/health-SP/idUSN1344003720070418">Baxter moves from drips to stem cell research</a> (reuters.com)
Categories
Research and Development0 TrackBacks
Listed below are links to blogs that reference this entry: Baxter moves from drips to stem cell research.
TrackBack URL for this entry: http://stemconnect.com/cgi-bin/mt/mt-t.cgi/148
Leave a comment